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Abstract 
Background: Ventilator-associated pneumonia (VAP) is a common nosocomial infection among hospitalized 
patients who have undergone intubation and mechanical ventilation for more than 48 hours. Patients admitted 
to the intensive care unit (ICU) are at risk of developing life-threatening VAP due to specific conditions, 
especially with Gram-negative pathogens with advanced drug resistance. Hereby, the control of these agents 
and its monitoring is of particular importance. In this study, the pattern of antibiotic resistance of Gram-
negative bacteria isolated from tracheal culture of patients with VAP investigated in ICU of Imam Khomeini 
Hospital of Ahwaz. 
Materials and Methods: In this cross-sectional study, tracheal samples were collected during April 2016 to 
April 2017 from patients who were on mechanical ventilation in ICU of Imam Khomeini Hospital in Ahwaz, 
Khuzestan province, southwest of Iran. After isolation, bacterial strains were identified using biochemical tests. 
Then, antimicrobial resistance pattern of these isolates investigated using standard disc diffusion according to 
clinical and laboratory standards institute 2016 (CLSI 2016) guidelines. 
Results: A total of 111 bacterial isolates were identified which were as following; Acinetobacter baumannii, 
Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Stenotrophomonas maltophilia, and 
Serratia marcescens, with prevalence of 54%, 19.8%, 14.4%, 6.4%, 4.5%, and 0.9%, respectively. Antibiotic 
susceptibility test of isolates showed that almost all isolates had high resistance to treatment antibiotics and 
were multi-drug resistance (MDR). The A. baumannii isolates were resistant to ciprofloxacin and 
piperacillin-tazobactam, but ampicillin-tazobactam had a good effect.  
Conclusion: The results of this study showed that patients admitted to ICU due to their conditions of treatment 
are more likely to develop VAP by Gram-negative pathogens. The empirical treatment of VAP due to 
predominant bacterial causes and emerging drug resistance has become more challenging. It requires to use of 
multidrug regimens for routine clinical practice. It should be noted that in order to appropriate antimicrobial 
therapy, precise and correct diagnosis is very important. 
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Ventilator-associated pneumonia (VAP) is the most 
common nosocomial infection diagnosed in the 
intensive care units (ICUs), affecting about 20% of 
patients in ICU and up to 30% of mechanically 
ventilated patients
1
. The mortality rate of VAP has 
been estimated to be 25 to 50%, and can reach up to 
75% in some specific settings or when lung infection 
is caused by high-risk pathogens, which is higher 
than those of other nosocomial infections
2
. In 
addition, VAP is associated with significant 
morbidity, including prolonged mechanical 
ventilation, prolonged ICU stays, and consequently 
increased costs of hospitalization
3
. Ventilator-
associated pneumonia is defined as pneumonia that 
develops 48 h more or longer after mechanical 
ventilation is given by means of an endotracheal tube 
or tracheostomy, caused by microbial pathogens not 
present or incubating at the time mechanical 
ventilation was commenced
4
. It may be of two types: 
first, early-onset VAP that is defined as VAP that 
happens within the first four days of ventilation, and 
second, late-onset VAP which is defined as VAP that 




Delays in diagnosis of VAP and thus delay in starting 
appropriate antibiotic therapy may be result in worse 
outcomes in the patients. On the other hand, an 
inappropriate diagnosis may lead to unnecessary 
treatment and following complications and risks 
associated with therapy. Therefore, early and 
accurate diagnosis of the causative agent and 
antibiotic susceptibility profile of the agent is 
fundamental in the management of patients with 
VAP
6
. The most frequently isolated causative 
bacterial agents are Gram-negative bacilli, which 
show a significant decline in sensitivities to generally 
prescribed antimicrobial agents. It has been reported 
that Gram-negative bacilli, such as Pseudomonas 
aeruginosa, Escherichia coli, Klebsiella pneumoniae, 
and Acinetobacter species, account for more than 
60% of VAP cases
7,8
. Of note, isolated Acinetobacter 
strains are practically resistant to all commonly used 
antibiotics
9
. However, some authors have reported that 
some Gram-positive bacteria have become 
increasingly more common, with Staphylococcus 
aureus being the predominant isolate
7,10
.  
As the kind of causative the pathogens and the 
antimicrobial susceptibility profile of them may vary 
depending on geographical region and hospital, data of 
microbial surveillance are essential for each area. 
Accordingly, this study was conducted to investigate 
the prevalence and pattern of antibiotic resistance of 
Gram-negative bacteria isolated from tracheal culture 
of patients with VAP was investigated in intensive 
care units of Imam Khomeini Hospital of Ahwaz in 
2017. 
Methods 
Ethics statement: The ethics committee of School of 
Medicine, Ahvaz Jundishapur University of Medical 
Sciences was approved this study 
(IR.AJUMS.REC.1396.615).  
Patients, Isolation and Identification: This cross 
sectional study was performed in intensive care 
medicine of Imam Khomeini Hospital of Ahwaz, 
Khuzestan province, southwest of Iran, with 
collaboration of Bacterial laboratory. Patients who 
were on mechanical ventilation for at least 5 days in 
ICU, who had CPIS values including fever greater 
than 38°C, leukocytosis, oxygenation or progressive 
radiographic infiltrate, were included in our study.  
Exclusion criteria included extrapulmonary infection 
sources, surgical history and any previous antibiotic 
therapy <48 h before the study. 
Bronchoalveolar lavage (BAL) fluid and endotracheal 
aspiration were obtained from all enrolled patients by 
bronchoscopy. Samples are immediately transported to 
microbiology laboratory for bacteriological analysis. 
Standard conventional biochemical tests for 
identification of the isolates were performed on 
colonies from primary cultures
11
. In addition, our 
study was included demographical information such as 
age, sex, underlying clinical condition, duration of 
hospitalization, and Duration of intubation was noted 
for evaluation of underlying factors for incidence of 
VAP. 
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Antimicrobial Susceptibility Testing: Standard disc 
diffusion method which is recommended by clinical 
laboratory and standard institute 2016 (CLSI 2016) 
was carried on evaluate antimicrobial susceptibility 
of the isolate microorganisms
12
. Accordingly, 
susceptibility of the isolates to following antibiotics: 
amikacin (30 μg/disk), 
trimethoprim/sulfamethoxazole (1.25/23.75 μg/disk), 
cefepime (30 μg/disk), ceftriaxone (30 μg/disk), 
piperacilin/tazobactam (100/10 μg), ciprofloxacin (5 
mg), meropenem (10 μg/disk), ceftazidime (30 
μg/disk) and ampicillin-sulbactam (10/10 μg) (Mast 
Co., Darmstadt, Germany) were examined. In 
addition, minimum inhibitory concentrations (MICs) 
were determined by the E-test method according to 
the manufacturer’s guidelines for colistin against 
A.baumannii, K. pneumoniae, and P.aeruginosa 
(Liofilchem Co., Roseto, Italy). The MIC was read 
where inhibition of growth intersected the E-test 
strip. When small colonies grew within the zone of 
inhibition or a haze of growth occurred around MIC 
end points, the highest MIC intersect was recorded. 
For standard strain, E. coli ATCC 25922 was used. 
Statistical analysis: SPSS version 22.0 (IBM Corp., 
Armonk, NY, USA) was applied for statistical 
analysis. Chi-square test was used for the comparison 
between the categorical variables. A p value <0.05 
was considered to be statistically significant. 
Results 
In the present study, from April 2016 to April 2017, 
111 bacterial isolates were collected from patients 
who were on mechanical ventilation in ICU of Imam 
Khomeini Hospital in Ahwaz. Among them 50.4% 
were male and 49.6% were female, which is not 
significantly different. Their mean age was 56 years. 
Most bacterial isolates were related internal ICU 
patients and internal surgical ICU. 
Different bacterial species were isolated. The 
bacterial strains were identified as following; 
Acinetobacter spp., P. aeruginosa, K. pneumoniae, 
E. coli, Stenotrophomonas maltophilia, and Serratia 
marcescens, with prevalence of 54% (n=60), 19.8% 
(n=22), 14.4% (n=16), 6.4% (n=7), 4.5% (n=5), and 
0.9% (n=1), respectively.  
All of A. baumannii isolates were resistant to 
ciprofloxacin, Piperacilin/Tazobactam and 
Meropenem antibiotics. Antibiotic susceptibility to A. 
baumannii isolates indicates that isolates causing VAP 
infection have high resistance to common antibiotics. 
The most active antibiotic against tested A. baumannii 
isolates were ampicillin-sulbactam and trimethoprim-
sulfamethoxazole, with susceptibility rate of 9% and 
4%, respectively. In this study, all of A. baumannii 
isolates were classified as multidrug resistant (MDR) 
strains (resistant to at least 3 different classes of 
antibiotics). The results of antimicrobial susceptibility 
test of A. baumannii isolates from VAP patients is 
indicated in Table 1. 
The present study indicated that all of P. aeruginosa 
isolates were resistant to ampicillin-sulbactam. High 
resistance rates were detected for trimethoprim-
sulfamethoxazole (86.4%), ceftriaxone (72.2%), 
meropenem (72.2%), cefepime (63.6%), and amikacin 
(59.1%). Table 2 illustrates the results of antimicrobial 
susceptibility testing of P. aeruginosa isolates. 
Our results indicated that K. pneumoniae isolates show 
the highest resistance to ampicillin-sulbactam, 
cefepime, ceftriaxone (whit resistance rate of 81.3%). 
The most active antibiotics were amikacin and 
levofloxacin (Table 3). In addition, the antibiotics 
susceptibility results showed that all of S. maltophilia 
isolates were resistant to cefepime, ceftriaxone, 
ciprofloxacin, piperacilin/tazobactam, meropenem, 
levofloxacin, and ampicillin-sulbactam. Only two 
isolates (28.6%) were susceptible to amikacin and 
trimethoprim-sulfamethoxazole. 
Discussion 
Ventilator-associated pneumonia causative pathogens 
generally are antibiotic resistant strains in many cases, 
it is commonly problematic to choose appropriate 
antibiotics. Furthermore, the mortality rate has been 
described to increase if an early antibiotic treatment is 
not provided to patients with VAP. Therefore, in order 
to start suitable empirical antibiotic therapy clinicians, 
need to identify predominant causative agents of VAP 
in ICU or any specific clinical setting and their 
antimicrobial susceptibility profile. Although, 
establishing a diagnosis of VAP, based on pathology 
or histology plus culture of the lung tissue, is 
considered the best available gold standard, but it has a 
considerable degree of uncertainty
13-15
. The risk 
factors for VAP include age, severity of illness or 
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injury, previous hospitalization prior to admission to 
the intensive care unit, mechanical ventilation time or 
tracheal intubation, and hospital stay in ICU, back 
rest, illness Underlying conditions, chronic heart 
disease, neurological damage, trauma, heart and 
internal surgery, previous use of corticosteroids, or 
previous antibiotic therapy
16,17
. VAP diagnosis is 
based on clinical criteria, chest X-ray and 
microbiological tests. Identification of each of the 
potential bacterial VAPs and the exact identification of 
each one to select the best antibiotic treatment and to 




In the present study, A. baumannii was shown to be 
the most common causative pathogen of VAP at ICU, 
and P. aeruginosa, K. pneumonia, S. maltophilia and 
Table 1: The results of antimicrobial susceptibility testing of A.baumannii isolates from VAP patients. 
Antibiotics Resistance. NO (%) Intermediate .NO (%) Susceptible. NO (%) 
Amikacin (AMK) 58   ( 96.7) 0 2 (3.3) 
Cefepime (FEP)  59 (98.3) 0 1 (1.7) 
Ceftriaxone (CRO) 59 (98.3) 0 1 (1.7) 
Ciprofloxacin (CIP) 60 (100) 0 0 
Piperacilin/Tazobactam (TZP) 60 (100) 0 0 
Trimethoprim-Sulfamethoxazole (SXT) 55 (91.7) 1 (1.7) 4 (6.6) 
Meropenem (MEM) 60 (100) 0 0 
Ceftazidime (CAZ) 59 (98.3) 0 1 (1.7) 
Ampicillin-Sulbactam (SAM) 46 (76.7) 5 (8.3) 9 (15) 
Colistin (CST) 0 (0%) 0 (0%) 60 (100) 
 
 Table 2: The results of antimicrobial susceptibility testing of P. aeruginosa isolates from VAP patients. 
Antibiotics Resistance. NO (%) Intermediate .NO (%) Susceptible. NO (%) 
Amikacin (AMK) 13   ( 59.1) 2 (9.1) 7 (31.8) 
Cefepime (FEP)  14 (63.6) 1 (4.5) 7 (31.8) 
Ceftriaxone (CRO) 16 (72.2) 5 (22.7) 1 (4.5) 
Ciprofloxacin (CIP) 12 (54.5) 1  (4.5) 9 (40.9) 
Piperacilin/Tazobactam (TZP) 14 (63.6) 0 8 (36.4) 
Trimethoprim-Sulfamethoxazole (SXT) 19 (86.4) 1 (4.5) 2 (9.1) 
Meropenem (MEM) 16 (72.2) 1  (4.5) 9 (40.9) 
Ceftazidime (CAZ) 12 (54.5) 1  (4.5) 1 (1.7) 
Ampicillin-Sulbactam (SAM) 22 (100) 0 0 
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S. marcescens followed A. baumannii in that order. 
This finding is similar to the result reported by 
Hashemian et al. in Iran
20
. Unfortunately, these 
bacterial strains are well known by their very high 
resistance to multiple antimicrobial, and except 
appropriate antibiotic therapy is administered early, 
mortality rate is significantly high
21
. Resistance is 
mediated by several mechanisms such as multiple 
efflux pumps expressed intrinsically or up regulated 
by mutation
22
. Increase in incidence of MDR isolates 
of Acinetobacter spp., P. aeruginosa and K. 
pneumoniae was observed in many parts of word, 
and some the isolates are susceptible only to 
colistin
23
. In an investigation in Greece, which 
provided original data on the prevalence of Gram-
negative bacteria in patients admitted to ICU, A. 
baumannii, P. aeruginosa and K. pneumoniae were 
the most common causative agents of VAP
24
. In 
another study, it has been notified that VAP 
associated with P. aeruginosa which are resistant to 




VAP causative pathogens are varied based on case 
mix, methodology of sampling and local resistance 
profiles. According to the study conducted by 
Charles et al. in India, 72.2% of VAP patients had 
mono microbial and 27.8% had poly-microbial 
infection
26
. Moreover, they reported that half of 
isolates associated with late-onset VAP were MDR, 
while 22% isolates obtained from patients with early-
onset VAP were MDR. 
In the present study, results of antimicrobial 
susceptibility testing of the isolates illustrate the 
highly resistant to the commonly used drugs. Among 
A. baumannii strains, except for ampicillin-sulbactam, 
more than 95% of isolates were resistant to the tested 
antibiotics. In addition, all isolates showed MDR 
phenotypes. In a study conducted by Kazemi et al. it 
has been shown that resistance rates of A. baumannii 
isolates against rifampicin, gentamicin, meropenem, 
piperacillin, ceftazidime, and colistin were 46%, 67%, 
100%, 98%, 96%, and 0%, respectively
27
.  
Our results indicated that all of K. pneumoniae 
isolates, which contained 14.4% of the isolates, were 
MDR and resistant to at least four antibiotic classes. 
Moreover, amikacin, levofloxacin and 
piperacilin/tazobactam showed the best activity on K. 
pneumoniae isolates, and other antibiotics had no 
significant effect on these isolates from VAP patients. 
Yadegarynia et al, conducted a study on 62 K. 
pneumonia isolates from clinical samples of ICU and 
general wards during one year
28
. The least resistance 
Table 3: The results of antimicrobial susceptibility testing of K. pneumoniae isolates from VAP patients. 
Antibiotics Resistance. NO (%) Intermediate .NO (%) Susceptible. NO (%) 
Amikacin (AMK) 7   ( 43.8) 0 9 (56.3) 
Cefepime (FEP)  13 (81.3) 0 3 (18.8) 
Ceftriaxone (CRO) 13 (81.3) 1 (6.3) 1 (6.3) 
Ciprofloxacin (CIP) 12 (75) 3 (18.8) 1 (6.3) 
Piperacilin/Tazobactam (TZP) 11 (68.8) 0 5 (31.3) 
Trimethoprim-Sulfamethoxazole (SXT) 10 (62.5) 2 (12.5) 4 (25) 
Meropenem (MEM) 11 (68.8) 1 (6.3) 4 (25) 
Levofloxacin (LVX) 8 (50) 1 (6.3) 7 (43.8) 
Ampicillin-Sulbactam (SAM) 13 (81.3) 0 3 (18.8) 
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was related to colistin (4.8%) and amikacin (14.5%), 
respectively, and the most resistance was observed 
against ciprofloxacin (66.1%), ceftriaxone (62.9%) 
and gentamicin (59.7%), respectively. Resistance to 
imipenem was observed among 38.7% of the isolates. 
Conclusion 
It has been reported that mortality of VAP associated 
with Gram-negative bacteria is high
29
 . Data from the 
available literature confirm that there is a direct 
association between antimicrobial resistance profiles 
and mortality in ICU patients. The results of this 
study showed that patients admitted to ICU due to 
their conditions of treatment are more likely to 
develop VAP by Gram-negative pathogens. In the 
present study we focused on Gram-negative bacteria 
isolated from patients in ICU and it founded that the 
major of them were drug resistant microorganism, 
including A. baumannii, P. aeruginosa and K. 
pneumoniae. It should be noted that precise and 
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